原 著
2026
_ スタッフ *責任著者
Yamada K,Nishizawa D, Arita H, Hanaoka K, Yajima C, Kato J, Ogawa S, Hiranuma A, Hasegawa J,
Ebata Y,Nakayama K, Iseki M,Ikeda K.
Dopamine transporter gene (SLC6A3) polymorphism rs2963257 and chronic pain
susceptibility in a Japanese population.
Pain Rep in press.
*Owada H,Nishizawa D, Mieda T, Tsujita M, Nakagawa H, Yamaguchi S, Tsuchida R, Yokoshima Y,
Kitamura A, Hayashida M, Fukuda K, Ichinohe T,Ikeda K, Kurano M, Sumitani M, Uchida K (2026)
The rs10781468 Genetic Polymorphism of the Gαq (GNAQ) Gene Is Associated
With Responsiveness to Opioid Analgesics in Patients With Postoperative
and Cancer Pain: An Exploratory Study
(Open Access)
Neuropsychopharmacol Rep46(3):e70148.査読有 doi: 10.1002/npr2.70148.
Nakagawa H,*Nishizawa D, Mieda T, Tsujita M, Kasai S, Hasegawa J,Nakayama K, Ebata Y, Kitamura, Hayashida M,
*Ikeda K.
Sex difference in effect of the OPRM1 gene A118G (rs1799971) single-nucleotide
polymorphism on the requirement for postoperative fentanyl in Japanese
patients who underwent laparoscopic-assisted colectomy.
(Open Access)
Neuropsychopharmacol Rep46(2):e70140. 査読有 doi: 10.1002/npr2.70140.
*Ohi K,Nishizawa D, Fujikane D, Hasegawa J, Sato N, Tanioka F, Sugimura H,Ikeda K, Shioiri T.
Genetic predispositions for anxiety disorders and major depressive disorder
affect current dietary habits in older patients with lifestyle-related
diseases short title: Genetic risks for anxiety and depression and dietary
habits.
(Open Access)
Int J Neuropsychopharmacol29(4):pyag014. 査読有 doi: 10.1093/ijnp/pyag014.
*Hagihara H, Koshimizu H, Hattori S, Shoji H, Tanaka M, Ikeda K, *Miyakawa T (2026)
Hyper-maturity and accelerated aging in the hippocampus of mouse models
of neuropsychiatric disorders with anxiety-like behavior.
(Open Access)
Neuropsychopharmacology51(5):856-867. 査読有 doi: 10.1038/s41386-025-02237-6.
総 説
2026
_ スタッフ *責任著者
*Uchida H, Gobbi G, Zohar J, Young AH, Rujescu D, Huang MC, Sundram S, Atwoli
L, Vukovic J, *Ikeda K.
Global perspectives on CNS drug innovation: achievements, barriers, and
priorities for the next decade.
(Open Access)
Int J Neuropsychopharmacolin press. doi: 10.1093/ijnp/pyag023.
Kamijo S, Miwa H, *Ikeda K.
Autism spectrum disorder: Integrating genetic and environmental risk.
Cells15(11):985. 査読有 doi: 10.3390/cells15110985.
*Ide S, Nishitani Y, Sumitani M, Minami M, Isa T, Iseki M, Ohkura M, Okamoto
H, Kikuchi T, Sekino Y, Takahashi H, Takeuchi K, Nitta A, Honjo T, Matsumoto
H, Miyakawa T, Murai T, Matsumoto T, Nakagome K, Ikeda K.
Addiction-related problems in Japan: A regional perspective.
(Open Access)
Addiction 121(5):1316-1324. 査読有 doi: 10.1111/add.70307.
学会等発表（招待講演）
2026
_ スタッフ *学会発表者
その他の発表
2026
_ スタッフ
*池田和隆 (2026)
アディクションを引き起こす神経伝達物質システム [講演]
藤田医科大学ブレインサイエンスセミナー, 藤田医科大学, 豊明 [2026/04/22].
学会等発表（その他）
2026
_ スタッフ *学会発表者
*Nakamoto Y, Nakamura K,Ikeda K, Yoshii M (2026)
Gender and age differences in association between translocator protein
18 kDa (TSPO) gene polymorphism and trait anxiety in normal human subjects.
37th CINP World Congress of Neuropsychopharmacology, Glasgow, UK [2026/06/28].
*Nago-Iwashita Y, Kanata T, Oba M, Ikeda K, Nishizawa D (2026)
Association of alcohol-related genetic polymorphisms with problematic alcohol
use and suicidal ideation.
37th CINP World Congress of Neuropsychopharmacology, Glasgow, UK [2026/06/28].
*Moriya Y, Saito-Moriya R, Nago-Iwashita Y, Sora I, Maki SA, Aoyama H,Ikeda K(2026)
Low-dose novel FLT3 inhibitor demonstrates non-opioid analgesic efficacy
in thermal and inflammatory pain models.
37th CINP World Congress of Neuropsychopharmacology, Glasgow, UK [2026/06/28].
*Nishizawa D, Hasegawa J,Nakayama K, Fukuda K-i, Ichinohe T, Nagashima M, Hayashida M, Trang T,Ikeda K(2026)
RUNX1 variant rs2236431 is associated with postoperative opioid analgesic
requirements in humans.
37th CINP World Congress of Neuropsychopharmacology, Glasgow, UK [2026/06/28].
*Enomoto A, Ohka S,Nishizawa D, Ogai Y, Kasai S, Ide S, Hasegawa J, Nakayama K, Hayashida M, Matsuura N, Ichinohe T, Fukuda K,Ikeda K(2026)
GABRA5 rs35399885 single nucleotide polymorphism is significantly associated
with sensory hypoesthesia and pain sensitivity.
37th CINP World Congress of Neuropsychopharmacology, Glasgow, UK [2026/06/28].
*Yamaguchi Y, Kasai S, Hasegawa J,Ikeda K(2026)
Smoking is associated with eating habits during development.
37th CINP World Congress of Neuropsychopharmacology, Glasgow, UK [2026/06/27].
*Ide S, Ikekubo Y, Uhl GR, Sora I, Ikeda K (2026)
Dopaminergic hyperactivity enhances persistent intracranial self-stimulation
with reward delivered at random responses within fixed response blocks.
37th CINP World Congress of Neuropsychopharmacology, Glasgow, UK [2026/06/27].
特記事項
2026
_ スタッフ
*Ikeda K, Krystal JH, Saito T (2026)
In memoriam—Shigeto Yamawaki, M.D., Ph.D. (1954–2026).
Neuropsychopharmacologydoi: 10.1038/s41386-026-02482-3.
Zohar J, Ikeda K (2026)
Spotlight Session 5: The Way Forward: Major Significant Collaboration (Joint
meeting with the leadership of WFSBP, WPA, ECNP, and CINP) [座長]
37th CINP World Congress of Neuropsychopharmacology, The Scottish Event
Campus, Glasgow, UK [2026/06/29].
Ikeda K(2025)
"Hikikomori" (Social Withdrawal). [座長] ACONAMI 2025, Tokyo(NCNP)[2025/9/24].
Bai YM,Ikeda K(2026)
Keynote Lecture 6 [座長]
37th CINP World Congress of Neuropsychopharmacology, The Scottish Event
Campus, Glasgow, UK [2026/06/29].